An Open-Label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine alpha4beta2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-Fertile Female (Non-Nicotine Users) Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 11 Sep 2009 Actual end date (Aug 2009), actual number of patients (11) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2009 New trial record